NCT04715217 - Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 4, 2021

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2025

Conditions

Lymphoma, B-Cell

Interventions

BIOLOGICAL

CD19-CD22 CAR-T cells

A autologous doping CAR - T cells injection targets with CD19 and CD22，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion CD19-CD22 CAR-T cells .

Trial Locations (1)

030013

RECRUITING

Hematology Department of ShanXi Cancer Hospital, Taiyuan